New, positive results show Ilumetri improves well-being of patients with plaque psoriasis

Key takeaways:

• Mean PASI scores decreased from 13.4 at baseline to 1.6 at week 28.
• Mean DLQI scores decreased from 12.3 at baseline to 3.1 at week 28.

Ilumetri significantly improved well-being in patients with moderate to severe plaque psoriasis after 16 weeks, Almirall announced in a press release.

According to the press release, which followed the presentation of results for the POSITIVE study at the 25th World Congress of Dermatology in Singapore, patients with moderate to severe plaque psoriasis being treated with Ilumetri (tildrakizumab) achieved significant improvement in well-being after 16 weeks of treatment and maintained this improvement up to week 28.

“At Almirall, we have long strived to improve patient quality of life by taking a holistic approach to skin diseases that captures the full impact of these conditions,” Volker Koscielny, chief medical officer at Almirall, said in the release. “The POSITIVE study marks a groundbreaking milestone in dermatology research and its preliminary findings reveal a notable enhancement in the well-being of individuals with psoriasis who were treated with tildrakizumab.”

According to the abstract presented at the 25th World Congress of Dermatology, study results showed that the well-being level at baseline of 263 patients (mean age, 46.3 years; 65.8% men), according to the 5-item WHO Well-being Index, was comparable to the well-being of patients with other diseases such as breast cancer. However, after being treated with tildrakizumab for 16 weeks, patients achieved a well-being similar to the general population.

At week 28, mean PASI scores decreased from 13.4 at baseline to 1.6 (P < .001), according to the abstract. At week 28, 85.1% of patients achieved PASI responses less than or equal to 3, whereas 55.3% achieved responses less than or equal to 1.

Also at week 28, mean DLQI scores decreased from 12.3 at baseline to 3.1 (P < .001). Mean scores on the Treatment Satisfaction Questionnaire for Medication showed that tildrakizumab scored 77.2 for effectiveness, 81.6 for convenience and 78.3 for global satisfaction.

“These initial results reinforce our conviction that we are on the right track in fulfilling our commitment to offer healthcare professionals and patients innovative solutions that effectively address their unmet needs,” Koscielny said in the release.

Reference:

Mrowietz U, et al. Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: 28-week interim data of the phase IV POSITIVE study. Presented at: 25th World Congress of Dermatology; July 3-8, 2023; Singapore.